marketcaparena
Search

    KYNB

    KYNTRA BIO, INC.

    Company overview

    Market capitalization
    $27.94M
    Employees
    34
    Latest publication
    2026-09-29
    About KYNTRA BIO, INC.

    Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue-1,474,000USD3,738,000USD1,278,000USD1,076,000USD1,348,000USD2,739,000USD-123,256,000USD46,333,000USD
    Cost Of Revenue2,000USD4,106,000USD278,000USD134,000USD306,000USD579,000USD-20,666,000USD5,295,000USD
    Gross Profit-1,476,000USD-368,000USD999,000USD942,000USD1,042,000USD2,160,000USD-102,590,000USD41,038,000USD
    Research Development6,821,000USD7,566,000USD7,268,000USD1,209,000USD5,865,000USD9,175,000USD1,486,000USD21,708,000USD
    Selling General Administrative9,266,000USD5,862,000USD7,250,000USD5,295,000USD7,057,000USD8,106,000USD13,320,000USD9,362,000USD
    Total Operating Expenses16,098,000USD13,428,000USD14,519,000USD6,312,000USD12,701,000USD16,954,000USD-10,934,000USD57,816,000USD
    Operating Income-17,574,000USD-13,818,000USD-13,512,000USD-5,370,000USD-11,659,000USD-14,794,000USD-91,656,000USD-16,778,000USD
    Total Other Income Expense Net29,547,000USD-1,314,000USD-1,097,000USD-7,776,000USD-2,116,000USD-1,970,000USD4,067,000USD-294,000USD
    Interest Expense2,368,000USD2,427,000USD2,413,000USD2,083,000USD2,009,000USD2,257,000USD2,217,000USD4,994,000USD
    Income Before Tax11,973,000USD-15,132,000USD-14,609,000USD-13,146,000USD-13,775,000USD-16,764,000USD-87,589,000USD-17,072,000USD
    Income Tax Expense-1,000USD66,000USD-389,000USD—-92,000USD2,000USD-52,000USD12,000USD
    Discontinued Operations0USD———————
    Net Income11,974,000USD-15,198,000USD-14,220,000USD148,473,000USD-7,603,000USD4,639,000USD17,982,000USD-17,084,000USD
    Interest Income—1,113,000USD1,315,000USD931,000USD286,000USD413,000USD204,000USD1,472,000USD
    Net Interest Income—-1,314,000USD-1,098,000USD-1,152,000USD-1,723,000USD-1,844,000USD6,731,000USD-597,000USD
    Tax Provision—0USD0USD0USD-92,000USD2,000USD-52,000USD3,000USD
    Net Income From Continuing Ops—-15,132,000USD-14,610,000USD-13,146,000USD-13,683,000USD-16,766,000USD-87,537,000USD-48,292,000USD
    Ebitda—-13,818,000USD-9,299,000USD-10,871,000USD-11,545,000USD-14,180,000USD-91,100,000USD-12,237,000USD
    Reconciled Depreciation—7,000USD8,000USD192,000USD221,000USD327,000USD352,000USD739,000USD
    Ebit——-9,307,000USD-11,063,000USD-11,766,000USD-14,507,000USD-91,452,000USD-12,976,000USD
    Depreciation And Amortization——8,000USD192,000USD221,000USD327,000USD352,000USD739,000USD
    Unclassified Operating Expenses——————-25,740,000USD26,746,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue6,440,000USD29,621,000USD46,803,000USD140,734,000USD235,309,000USD176,319,000USD256,577,000USD212,958,000USD
    Cost Of Revenue556,000USD15,561,000USD3,962,000USD20,280,000USD449,192,000USD8,869,000USD1,147,000USD235,839,000USD
    Gross Profit5,884,000USD14,060,000USD42,841,000USD120,454,000USD-213,883,000USD167,450,000USD255,430,000USD-22,881,000USD
    Research Development23,517,000USD95,692,000USD266,473,000USD296,791,000USD387,043,000USD252,924,000USD209,265,000USD235,839,000USD
    Selling General Administrative27,709,000USD49,330,000USD86,483,000USD124,688,000USD123,925,000USD——63,812,000USD
    Total Operating Expenses51,226,000USD164,476,000USD365,562,000USD421,479,000USD74,647,000USD359,330,000USD344,744,000USD299,651,000USD
    Operating Income-45,895,000USD-150,416,000USD-322,721,000USD-301,025,000USD-288,530,000USD-191,880,000USD-89,314,000USD-86,693,000USD
    Interest Income2,943,000USD5,296,000USD7,594,000USD7,596,000USD————
    Interest Expense8,759,000USD8,247,000USD8,095,000USD1,440,000USD1,075,000USD2,402,000USD2,876,000USD10,991,000USD
    Net Interest Income-5,816,000USD-2,951,000USD-501,000USD6,156,000USD-2,153,000USD———
    Income Before Tax-58,294,000USD-153,367,000USD-323,222,000USD-293,296,000USD-289,676,000USD-188,931,000USD-76,642,000USD-86,116,000USD
    Income Tax Expense-90,000USD-269,000USD-252,000USD358,000USD347,000USD360,000USD328,000USD304,000USD
    Tax Provision-90,000USD-269,000USD-252,000USD358,000USD347,000USD———
    Net Income183,452,000USD-47,579,000USD-284,232,000USD-293,654,000USD-290,023,000USD-189,291,000USD-76,970,000USD-86,420,000USD
    Net Income From Continuing Ops-58,204,000USD-153,098,000USD-322,970,000USD-293,654,000USD-290,023,000USD———
    Ebit-46,643,000USD-145,120,000USD-315,127,000USD-293,429,000USD-348,530,000USD-186,327,000USD-73,766,000USD-75,125,000USD
    Ebitda-45,895,000USD-142,428,000USD-305,197,000USD-282,825,000USD-333,721,000USD-164,280,000USD-52,312,000USD-68,563,000USD
    Depreciation And Amortization748,000USD2,692,000USD9,930,000USD10,604,000USD14,809,000USD22,047,000USD21,454,000USD6,562,000USD
    Reconciled Depreciation748,000USD2,692,000USD9,930,000USD10,604,000USD14,809,000USD———
    Total Other Income Expense Net-12,399,000USD-2,951,000USD-501,000USD7,729,000USD-1,146,000USD2,949,000USD12,672,000USD577,000USD
    Unclassified Operating Expenses—19,454,000USD12,606,000USD—-436,321,000USD106,406,000USD135,479,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets101,078,000USD109,629,000USD119,594,000USD137,014,000USD178,055,000USD165,213,000USD214,525,000USD264,421,000USD
    Cash And Equivalents50,644,000USD———————
    Cash And Short Term Investments91,318,000USD87,237,000USD88,978,000USD117,975,000USD23,367,000USD33,609,000USD50,482,000USD131,003,000USD
    Short Term Investments40,674,000USD50,240,000USD41,106,000USD———0USD0USD
    Long Term Investments4,012,000USD8,026,000USD20,160,000USD3,035,000USD——0USD5,806,000USD
    Total Current Assets96,825,000USD101,355,000USD99,073,000USD133,423,000USD162,322,000USD148,529,000USD196,509,000USD244,529,000USD
    Other Current Assets833,000USD5,694,000USD6,136,000USD1,463,000USD134,956,000USD111,618,000USD142,391,000USD6,255,000USD
    Other Non Current Assets241,000USD———————
    Total Liabilities109,222,000USD———————
    Total Current Liabilities36,040,000USD28,114,000USD29,242,000USD35,973,000USD155,895,000USD73,390,000USD133,306,000USD190,530,000USD
    Other Current Liabilities23,112,000USD———————
    Other Non Current Liabilities67,000USD———————
    Total Stockholder Equity-30,144,000USD-9,290,000USD4,475,000USD-17,028,000USD-222,997,000USD-216,896,000USD-225,601,999USD-243,667,000USD
    Total Equity Including Noncontrolling Interest-8,144,000USD———————
    Deferred Revenue5,418,000USD———————
    Deferred Revenue Non Current2,620,000USD———————
    Net Receivables347,000USD5,040,000USD216,000USD10,121,000USD136,000USD147,000USD481,000USD83,334,000USD
    Inventory3,384,000USD3,384,000USD3,743,000USD3,864,000USD3,863,000USD3,155,000USD3,155,000USD23,937,000USD
    Accounts Payable7,510,000USD5,094,000USD3,745,000USD5,093,000USD10,477,000USD7,282,000USD5,064,000USD9,238,000USD
    Common Stock41,000USD40,000USD1,012,000USD1,011,000USD1,011,000USD1,010,000USD1,008,999USD1,008,000USD
    Retained Earnings-1,709,271,000USD-1,721,245,000USD-1,706,047,000USD-1,691,827,000USD-1,892,463,000USD-1,884,860,000USD-1,889,499,000USD-1,907,481,000USD
    Accumulated Other Comprehensive Income-1,188,000USD-1,893,000USD-2,182,000USD-2,211,000USD-4,794,000USD-4,434,000USD-5,731,999USD-5,628,000USD
    Total Liab—118,919,000USD115,119,000USD119,529,000USD359,085,000USD340,142,000USD398,159,999USD466,121,000USD
    Other Current Liab—17,340,000USD20,183,000USD29,311,000USD44,374,000USD43,599,000USD128,242,000USD139,462,000USD
    Capital Stock—40,000USD1,012,000USD1,011,000USD1,011,000USD1,010,000USD1,009,000USD1,008,000USD
    Cash—36,997,000USD47,872,000USD117,975,000USD23,367,000USD33,609,000USD50,482,000USD131,003,000USD
    Current Deferred Revenue—5,680,000USD5,314,000USD5,104,000USD27,311,000USD22,509,000USD27,290,000USD28,858,000USD
    Net Debt—-36,997,000USD-47,872,000USD-96,935,000USD50,366,000USD39,810,000USD39,692,000USD-51,666,000USD
    Common Stock Shares Outstanding—4,047,000shares4,046,000shares4,044,000shares4,042,000shares100,954,000shares4,033,200shares4,020,600shares
    Non Current Assets Total—8,274,000USD20,521,000USD3,591,000USD15,733,000USD16,684,000USD18,016,000USD19,892,000USD
    Non Current Liabilities Total—90,805,000USD85,877,000USD83,556,000USD203,190,000USD266,752,000USD264,853,999USD275,591,000USD
    Non Current Liabilities Other—86,730,000USD85,622,000USD82,983,000USD80,810,000USD77,797,000USD76,698,000USD75,886,000USD
    Non Currrent Assets Other—248,000USD361,000USD556,000USD15,733,000USD16,684,000USD17,919,000USD4,390,000USD
    Net Working Capital—73,241,000USD69,831,000USD97,450,000USD6,427,000USD75,139,000USD63,203,000USD53,999,000USD
    Unclassified Non Current Liabilities—4,075,000USD——122,380,000USD115,536,000USD115,063,999USD126,926,000USD
    Unclassified Equity—1,713,768,000USD1,710,680,000USD1,674,988,000USD1,672,238,000USD1,670,378,000USD1,667,611,001USD1,667,426,000USD
    Short Term Debt———1,569,000USD73,733,000USD—34,000USD5,851,000USD
    Short Long Term Debt Total———21,040,000USD73,733,000USD73,419,000USD90,174,000USD79,337,000USD
    Unclassified Current Liabilities———-5,104,000USD-73,733,000USD—-27,324,000USD7,121,000USD
    Short Long Term Debt————73,733,000USD———
    Long Term Debt—————73,419,000USD73,092,000USD72,779,000USD
    Property Plant Equipment Net——————97,000USD9,696,000USD
    Property Plant Equipment Gross——————0USD9,696,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets119,594,000USD214,525,000USD423,529,000USD610,087,000USD773,821,000USD826,840,000USD857,397,000USD880,598,000USD
    Other Current Assets6,136,000USD142,391,000USD13,355,000USD14,083,000USD12,453,000USD10,160,000USD8,181,000USD7,634,000USD
    Total Liab115,119,000USD398,159,999USD585,728,000USD611,567,000USD544,708,000USD385,391,000USD321,991,000USD352,128,000USD
    Total Stockholder Equity4,475,000USD-225,601,999USD-204,166,000USD-21,447,000USD209,146,000USD422,178,000USD516,135,000USD509,199,000USD
    Other Current Liab20,183,000USD128,242,000USD166,236,000USD212,082,000USD156,813,000USD112,363,000USD80,789,000USD65,028,000USD
    Common Stock1,012,000USD1,008,999USD988,000USD942,000USD929,000USD914,000USD877,000USD854,000USD
    Capital Stock1,012,000USD1,009,000USD988,000USD942,000USD929,000USD———
    Retained Earnings-1,706,047,000USD-1,889,499,000USD-1,841,920,000USD-1,557,688,000USD-1,264,034,000USD-974,011,000USD-784,720,000USD-715,827,000USD
    Cash47,872,000USD50,482,000USD113,688,000USD155,700,000USD171,223,000USD678,393,000USD126,266,000USD89,258,000USD
    Cash And Short Term Investments88,978,000USD50,482,000USD235,586,000USD422,008,000USD405,190,000USD686,537,000USD533,757,000USD621,402,000USD
    Total Current Assets99,073,000USD196,509,000USD331,559,000USD492,826,000USD474,059,000USD755,110,000USD702,490,000USD690,015,000USD
    Total Current Liabilities29,242,000USD133,306,000USD217,668,000USD273,562,000USD225,497,000USD163,187,000USD102,745,000USD89,033,000USD
    Current Deferred Revenue5,314,000USD27,290,000USD12,740,000USD12,739,000USD19,033,000USD6,547,000USD490,000USD13,771,000USD
    Net Debt-47,872,000USD39,692,000USD56,767,000USD-65,815,000USD-71,503,000USD-638,631,000USD-74,380,000USD7,899,000USD
    Long Term Investments20,160,000USD0USD5,290,000USD9,409,000USD171,621,000USD———
    Short Term Investments41,106,000USD0USD121,898,000USD266,308,000USD233,967,000USD8,144,000USD407,491,000USD532,144,000USD
    Net Receivables216,000USD481,000USD41,053,000USD16,299,000USD25,401,000USD41,883,000USD153,665,000USD63,684,000USD
    Inventory3,743,000USD3,155,000USD41,565,000USD40,436,000USD31,015,000USD16,530,000USD6,887,000USD—
    Accounts Payable3,745,000USD5,064,000USD17,960,000USD30,758,000USD26,097,000USD24,789,000USD6,088,000USD9,139,000USD
    Accumulated Other Comprehensive Income-2,182,000USD-5,731,999USD-6,875,000USD-5,720,000USD-4,163,000USD-4,499,000USD-747,000USD-2,281,000USD
    Common Stock Shares Outstanding4,043,000shares100,044,000shares97,303,000shares93,582,000shares92,349,000shares89,854,000shares86,633,000shares84,062,000shares
    Non Current Assets Total20,521,000USD18,016,000USD91,970,000USD117,261,000USD299,762,000USD71,730,000USD154,907,000USD190,583,000USD
    Non Current Liabilities Total85,877,000USD264,853,999USD368,060,000USD338,005,000USD319,211,000USD222,204,000USD219,246,000USD263,095,000USD
    Non Current Liabilities Other85,622,000USD76,698,000USD72,034,000USD72,690,000USD43,634,000USD———
    Non Currrent Assets Other361,000USD17,919,000USD5,308,000USD7,354,000USD8,752,000USD5,505,000USD11,444,000USD7,565,000USD
    Net Working Capital69,831,000USD63,203,000USD113,891,000USD219,264,000USD248,562,000USD———
    Unclassified Equity1,710,680,000USD1,667,611,001USD1,642,653,000USD1,540,077,000USD1,475,485,000USD1,399,774,000USD1,300,725,000USD1,226,453,000USD
    Short Term Debt—34,000USD14,117,000USD10,292,000USD10,944,000USD13,518,000USD13,334,000USD—
    Short Long Term Debt Total—90,174,000USD170,455,000USD89,885,000USD99,720,000USD39,762,000USD51,886,000USD97,157,000USD
    Long Term Debt—73,092,000USD71,934,000USD—————
    Property Plant Equipment Net—97,000USD81,372,000USD100,498,000USD119,389,000USD63,253,000USD82,345,000USD127,198,000USD
    Property Plant Equipment Gross—0USD211,102,000USD251,277,000USD250,197,000USD———
    Unclassified Current Liabilities—-27,324,000USD6,615,000USD7,691,000USD12,610,000USD5,970,000USD2,044,000USD1,095,000USD
    Unclassified Non Current Liabilities—115,063,999USD224,092,000USD265,315,000USD275,577,000USD222,204,000USD219,246,000USD263,095,000USD
    Unclassified Non Current Assets—————2,972,000USD61,118,000USD55,820,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation0USD
    Stock Based Compensation2,135,000USD
    Change To Account Receivables-131,000USD
    Change To Inventory359,000USD
    Change To Liabilities7,805,000USD
    Change In Working Capital4,461,000USD
    Operating Cash Flow-17,878,000USD
    Capital Expenditures0USD
    Net Investments16,757,000USD
    Unclassified Investing Cash Flow3,934,000USD
    Investing Cash Flow20,691,000USD
    Net Common Stock Issuance-12,000USD
    Financing Cash Flow-12,000USD
    Effect Of Forex Changes On Cash-29,000USD
    Change In Cash2,772,000USD
    End Cash Flow50,644,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-15,198,000USD-14,220,000USD-13,146,000USD-7,603,000USD4,639,000USD17,982,000USD-17,084,000USD-15,544,000USD
    Depreciation7,000USD8,000USD192,000USD221,000USD327,000USD352,000USD739,000USD781,000USD
    Stock Based Compensation1,151,000USD1,189,000USD662,000USD1,873,000USD2,852,000USD178,000USD7,687,000USD8,588,000USD
    Other Non Cash Items153,000USD-17,444,000USD171,436,000USD400,000USD553,000USD-1,199,000USD3,472,000USD-1,258,000USD
    Change To Account Receivables-4,824,000USD-94,000USD552,000USD159,000USD-3,160,000USD9,221,000USD-21,920,000USD30,647,000USD
    Change To Inventory359,000USD122,000USD1,030,000USD1,351,000USD2,859,000USD4,506,000USD2,200,000USD1,792,000USD
    Change In Working Capital270,000USD12,139,000USD-160,329,000USD17,791,000USD-5,652,000USD-47,779,000USD-3,190,000USD-32,436,000USD
    Total Cash From Operating Activities-13,887,000USD-18,328,000USD-1,847,000USD12,682,000USD2,719,000USD-30,466,000USD-8,376,000USD-39,869,000USD
    Capital Expenditures0USD0USD-8,999USD-13,000USD-16,000USD-141,000USD-82,000USD-14,000USD
    Free Cash Flow-13,887,000USD-18,328,000USD-1,856,000USD12,669,000USD2,703,000USD-30,607,000USD-8,458,000USD-39,883,000USD
    Investments3,078,000USD-58,123,000USD-3,035,000USD0USD0USD1,658,000USD0USD—
    Total Cashflows From Investing Activities3,018,000USD-51,712,000USD87,160,000USD-13,000USD-16,000USD1,723,000USD755,000USD72,239,000USD
    Net Borrowings0USD-6,000USD-75,002,000USD3,000USD-5,000USD-4,000USD-16,000USD—
    Total Cash From Financing Activities-7,000USD-14,000USD-85,917,000USD-9,000USD-88,000USD5,000USD-127,000USD32,000USD
    Change In Cash-10,875,000USD-70,103,000USD94,608,000USD13,641,000USD4,022,000USD-28,825,000USD-9,711,000USD34,980,000USD
    Begin Period Cash Flow47,872,000USD117,975,000USD23,367,000USD106,200,000USD102,178,000USD131,003,000USD140,714,000USD105,734,000USD
    End Period Cash Flow36,997,000USD47,872,000USD117,975,000USD119,841,000USD106,200,000USD102,178,000USD131,003,000USD140,714,000USD
    Other Cashflows From Investing Activities-60,000USD6,411,000USD————837,000USD—
    Other Cashflows From Financing Activities-7,000USD-14,000USD-5,365,000USD-12,000USD-46,000USD-14,000USD-111,000USD-76,000USD
    Sale Purchase Of Stock—-37,000USD—-12,000USD-37,000USD—-111,000USD—
    Unclassified Investing Cash Flow——90,203,999USD————72,253,000USD
    Unclassified Financing Cash Flow——-5,550,000USD—————
    Issuance Of Capital Stock—————0USD0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income183,452,000USD-47,579,000USD-284,232,000USD-293,654,000USD-290,023,000USD-189,291,000USD-76,970,000USD-86,420,000USD
    Depreciation748,000USD2,692,000USD9,930,000USD10,604,000USD14,809,000USD22,047,000USD21,454,000USD6,562,000USD
    Stock Based Compensation6,576,000USD25,215,000USD50,767,000USD65,601,000USD71,161,000USD72,720,000USD66,267,000USD52,142,000USD
    Other Non Cash Items-195,550,000USD-868,000USD28,201,000USD1,086,000USD61,738,000USD1,496,000USD-3,797,000USD-30,000USD
    Change To Account Receivables-2,543,000USD-6,737,000USD3,433,000USD765,000USD25,180,000USD-11,973,000USD35,229,000USD-55,232,000USD
    Change To Inventory5,362,000USD22,284,000USD-1,695,000USD-10,999,000USD-14,158,000USD-9,175,000USD-6,887,000USD—
    Change In Working Capital-153,032,000USD-117,459,000USD-119,687,000USD70,430,000USD60,083,000USD174,630,000USD-85,659,000USD-48,398,000USD
    Total Cash From Operating Activities-4,774,000USD-137,999,000USD-315,021,000USD-145,933,000USD-82,232,000USD81,602,000USD-78,705,000USD-76,144,000USD
    Capital Expenditures-38,000USD-266,000USD-2,519,000USD-38,741,000USD-30,186,000USD-3,994,000USD-5,762,000USD-8,020,000USD
    Free Cash Flow-4,812,000USD-138,265,000USD-317,540,000USD-184,674,000USD-112,418,000USD77,608,000USD-84,467,000USD-84,164,000USD
    Investments-61,158,000USD125,213,000USD155,520,000USD127,851,000USD-396,786,000USD———
    Total Cashflows From Investing Activities35,419,000USD125,993,000USD153,657,000USD89,116,000USD-426,972,000USD452,487,000USD120,018,000USD-522,123,000USD
    Net Borrowings-75,010,000USD-40,000USD73,594,000USD-538,000USD-5,892,000USD———
    Total Cash From Financing Activities-86,028,000USD-255,000USD122,749,000USD46,776,000USD-563,000USD13,343,000USD-4,300,000USD13,875,000USD
    Dividends Paid-3,947,000USD-2,230,000USD——————
    Change In Cash-54,306,000USD-11,510,000USD-42,012,000USD-15,523,000USD-507,170,000USD552,127,000USD37,008,000USD-584,400,000USD
    Begin Period Cash Flow102,178,000USD113,688,000USD155,700,000USD171,223,000USD678,393,000USD126,266,000USD89,258,000USD673,658,000USD
    End Period Cash Flow47,872,000USD102,178,000USD113,688,000USD155,700,000USD171,223,000USD678,393,000USD126,266,000USD89,258,000USD
    Other Cashflows From Investing Activities96,615,000USD——-34,994,000USD-25,000,000USD—7,000USD184,000USD
    Other Cashflows From Financing Activities-82,081,000USD1,876,000USD748,000USD43,130,000USD-7,372,000USD-11,463,000USD-12,750,000USD-15,612,000USD
    Unclassified Operating Cash Flow153,032,000USD———————
    Unclassified Financing Cash Flow75,010,000USD——4,184,000USD12,701,000USD24,806,000USD8,450,000USD29,487,000USD
    Issuance Of Capital Stock—0USD48,407,000USD0USD0USD———
    Unclassified Investing Cash Flow———35,000,000USD25,000,000USD456,481,000USD125,773,000USD-514,287,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductDevelopment And Other Revenue246,000USD0001193125-26-219374
    Q1 2026Quarterly · 2026-03-31ProductDrug Product Revenue3,492,000USD0001193125-26-219374
    FY 2025Yearly · 2025-12-31GeographyChina0USD0001193125-26-108346
    FY 2025Yearly · 2025-12-31GeographyEurope5,643,000USD0001193125-26-108346
    FY 2025Yearly · 2025-12-31GeographyJapan797,000USD0001193125-26-108346
    FY 2025Yearly · 2025-12-31GeographyUnited States0USD0001193125-26-108346
    FY 2025Yearly · 2025-12-31ProductDevelopment And Other Revenue592,000USD0001193125-26-108346
    FY 2025Yearly · 2025-12-31ProductDrug Product Revenue5,848,000USD0001193125-26-108346
    Q3 2025Quarterly · 2025-09-30ProductDevelopment And Other Revenue119,000USD0001193125-25-274241
    Q3 2025Quarterly · 2025-09-30ProductDrug Product Revenue957,000USD0001193125-25-274241
    Q3 2025Quarterly · 2025-09-30GeographyEurope1,335,000USD0001193125-25-274241
    Q3 2025Quarterly · 2025-09-30GeographyJapan-378,000USD0001193125-25-274241
    Q3 2025Quarterly · 2025-09-30GeographyUnited States0USD0001193125-25-274241
    Q2 2025Quarterly · 2025-06-30ProductDevelopment And Other Revenue133,000USD0000950170-25-106549
    Q2 2025Quarterly · 2025-06-30ProductDrug Product Revenue1,215,000USD0000950170-25-106549
    Q2 2025Quarterly · 2025-06-30GeographyEurope1,171,000USD0000950170-25-106549
    Q2 2025Quarterly · 2025-06-30GeographyJapan44,000USD0000950170-25-106549
    Q2 2025Quarterly · 2025-06-30GeographyUnited States0USD0000950170-25-106549
    Q1 2025Quarterly · 2025-03-31ProductDevelopment And Other Revenue144,000USD0001193125-26-219374
    Q1 2025Quarterly · 2025-03-31ProductDrug Product Revenue2,595,000USD0001193125-26-219374
    Q1 2025Quarterly · 2025-03-31GeographyEurope814,000USD0001193125-26-219374
    Q1 2025Quarterly · 2025-03-31GeographyJapan1,781,000USD0001193125-26-219374
    Q4 2024Quarterly · 2024-12-31ProductDevelopment And Other Revenue416,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductDrug Product Revenue2,720,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyChina91,000USD0001193125-26-108346
    FY 2024Yearly · 2024-12-31GeographyEurope6,270,000USD0001193125-26-108346
    FY 2024Yearly · 2024-12-31GeographyJapan-2,854,000USD0001193125-26-108346
    FY 2024Yearly · 2024-12-31GeographyUnited States26,114,000USD0001193125-26-108346
    FY 2024Yearly · 2024-12-31ProductDevelopment And Other Revenue1,948,000USD0000950170-25-040280
    FY 2024Yearly · 2024-12-31ProductDrug Product Revenue27,673,000USD0000950170-25-040280
    FY 2024Yearly · 2024-12-31ProductLicense0USD0000950170-25-040280
    FY 2024Yearly · 2024-12-31ProductOther Revenue Patent Transfer0USD0000950170-25-040280
    Q3 2024Quarterly · 2024-09-30ProductDevelopment And Other Revenue385,000USD0001193125-25-274241
    Q3 2024Quarterly · 2024-09-30ProductDrug Product Revenue-262,000USD0001193125-25-274241
    Q2 2024Quarterly · 2024-06-30ProductDevelopment And Other Revenue269,000USD0000950170-25-106549
    Q2 2024Quarterly · 2024-06-30ProductDrug Product Revenue729,000USD0000950170-25-106549
    Q2 2024Quarterly · 2024-06-30GeographyEurope1,095,000USD0000950170-25-106549
    Q2 2024Quarterly · 2024-06-30GeographyJapan-366,000USD0000950170-25-106549
    Q2 2024Quarterly · 2024-06-30GeographyUnited States0USD0000950170-25-106549
    Q1 2024Quarterly · 2024-03-31ProductDevelopment And Other Revenue878,000USD0000950170-25-069203
    Q1 2024Quarterly · 2024-03-31ProductDrug Product Revenue24,486,000USD0000950170-25-069203
    Q1 2024Quarterly · 2024-03-31GeographyEurope1,021,000USD0000950170-25-069203
    Q1 2024Quarterly · 2024-03-31GeographyJapan-2,205,000USD0000950170-25-069203
    Q1 2024Quarterly · 2024-03-31GeographyUnited States25,670,000USD0000950170-25-069203
    FY 2023Yearly · 2023-12-31GeographyChina8,426,000USD0000950170-25-040280
    FY 2023Yearly · 2023-12-31GeographyEurope9,549,000USD0000950170-25-040280
    FY 2023Yearly · 2023-12-31GeographyJapan15,867,000USD0000950170-25-040280
    FY 2023Yearly · 2023-12-31GeographyUnited States12,961,000USD0000950170-25-040280
    Q3 2023Quarterly · 2023-09-30GeographyEurope625,000USD0000950170-24-125388
    Q3 2023Quarterly · 2023-09-30GeographyJapan695,000USD0000950170-24-125388
    Q3 2023Quarterly · 2023-09-30GeographyUnited States0USD0000950170-24-125388
    Q1 2023Quarterly · 2023-03-31GeographyEurope377,000USD0000950170-24-053554
    Q1 2023Quarterly · 2023-03-31GeographyJapan1,700,000USD0000950170-24-053554
    Q1 2023Quarterly · 2023-03-31GeographyOther23,000USD0000950170-24-053554
    FY 2022Yearly · 2022-12-31GeographyChina84,631,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31GeographyEurope33,820,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31GeographyJapan9,764,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31GeographyUnited States12,519,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31ProductDevelopment And Other Revenue24,189,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31ProductDrug Product Revenue11,086,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31ProductLicense22,590,000USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31ProductOther Revenue Patent Transfer0USD0000950170-24-020161
    FY 2022Yearly · 2022-12-31ProductProduct82,869,000USD0000950170-24-020161
    Q2 2022Quarterly · 2022-06-30GeographyEurope1,076,000USD0000950170-23-039070
    Q2 2022Quarterly · 2022-06-30GeographyJapan17,000USD0000950170-23-039070
    FY 2021Yearly · 2021-12-31GeographyChina0USD0000950170-23-004668
    FY 2021Yearly · 2021-12-31GeographyEurope1,130,000USD0000950170-23-004668
    FY 2021Yearly · 2021-12-31GeographyJapan2,056,000USD0000950170-23-004668
    FY 2021Yearly · 2021-12-31GeographyUnited States-2,224,000USD0000950170-23-004668
    FY 2021Yearly · 2021-12-31ProductDevelopment And Other Revenue70,275,000USD0000950170-24-020161
    FY 2021Yearly · 2021-12-31ProductDrug Product Revenue962,000USD0000950170-24-020161
    FY 2021Yearly · 2021-12-31ProductLicense116,434,000USD0000950170-24-020161
    FY 2021Yearly · 2021-12-31ProductOther Revenue Patent Transfer0USD0000950170-24-020161
    FY 2021Yearly · 2021-12-31ProductProduct47,638,000USD0000950170-24-020161
    FY 2020Yearly · 2020-12-31GeographyChina-90,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31GeographyEurope0USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31GeographyJapan4,281,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31GeographyOther90,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31GeographyUnited States4,625,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31ProductDevelopment And Other Revenue80,592,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31ProductDrug Product Revenue8,906,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31ProductLicense14,323,000USD0000950170-23-004668
    FY 2020Yearly · 2020-12-31ProductProduct72,498,000USD0000950170-23-004668
    FY 2019Yearly · 2019-12-31GeographyAll Other2,000USD0001564590-22-007632
    FY 2019Yearly · 2019-12-31GeographyChina20,967,000USD0001564590-22-007632
    FY 2019Yearly · 2019-12-31GeographyEurope145,641,000USD0001564590-22-007632
    FY 2019Yearly · 2019-12-31GeographyJapan-23,167,000USD0001564590-22-007632
    FY 2019Yearly · 2019-12-31GeographyUnited States113,134,000USD0001564590-22-007632
    FY 2019Yearly · 2019-12-31ProductAPIProduct-36,324,000USD0001564590-20-008161
    FY 2019Yearly · 2019-12-31ProductDevelopment And Other Revenue114,115,000USD0001564590-20-008161
    FY 2019Yearly · 2019-12-31ProductDrug Product1,700,000USD0001564590-20-008161
    FY 2019Yearly · 2019-12-31ProductLicense177,086,000USD0001564590-20-008161
    FY 2019Yearly · 2019-12-31ProductManufactured Product Other0USD0001564590-20-008161
    FY 2018Yearly · 2018-12-31GeographyChina0USD0001564590-21-009871
    FY 2018Yearly · 2018-12-31GeographyJapan64,800,000USD0001564590-21-009871
    FY 2018Yearly · 2018-12-31ProductDevelopment And Other Revenue125,913,000USD0001564590-21-009871
    FY 2018Yearly · 2018-12-31ProductDrug Product Revenue64,776,000USD0001564590-21-009871
    FY 2018Yearly · 2018-12-31ProductLicense22,269,000USD0001564590-21-009871
    FY 2018Yearly · 2018-12-31ProductProduct0USD0001564590-21-009871
    FY 2017Yearly · 2017-12-31ProductDevelopment And Other Revenue121,063,000USD0001564590-20-008161

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.